ClinicalTrials.gg
CompletedNCT00549978Updated Mar 4, 2022

Safety and Pharmacokinetics of Probucol and Cilostazol

A Phase 4 interventional study of Cilostazol and Probucol in Healthy, sponsored by Korea Otsuka Pharmaceutical Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to male participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-04.

Sponsored by Korea Otsuka Pharmaceutical Co., Ltd. (part of Otsuka Holdings Co., Ltd.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Male
01

Study summary

to investigate the safety and pharmacokinetics, in healthy adult male subjects

Read the detailed description

Safety and Pharmacokinetics of Probucol and Cilostazol when co-administered in Health Subjects

02

Conditions studied

  • Healthy

Keywords

  • Safety and Pharmacokinetics in healthy subjects
03

In context

Lead sponsor

Korea Otsuka Pharmaceutical Co., Ltd. is the lead sponsor of 42 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Korean
  • Gender: Male
  • Age: Over 20 and Under 40years, at time of
  • body weight: over 19.0 and Under 25.0
  • Subjects who meet the following criteria at the time of the screening examination
  • Subjects who have given their written informed consent prior to participation in the study
  • Subjects who are reliable and willing to make themselves available for the duration of the study and follow the study protocol

Exclusion criteria

Exclusion Criteria:

  • History or clinical evidence of significant respiratory, cardiovascular, renal, gastrointestinal, hepatic, endocrine, hematologic, neurologic, psychiatric, or other chronic disease, alcoholism, or drug abuse
  • Present or previous significant drug allergy to any prescription or over the counter medication
  • Blood collection exceeding 200ml within 4 weeks, 400ml within 12 weeks, or 1200ml within one year prior to scheduled study drug administration
  • Body weight: under 50Kg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Other
    1

    Two compartments with cross-over and parallel

    Drug: Cilostazol

  • Other
    2

    Two compartments with cross-over and parallel

    Drug: Probucol

Interventions

  • cilostazol, then cilostazol/probucol

  • Probucol probucol/ cilostazol

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic parameters, Number of adverse events

    Time frame: during study follow-up period

Secondary outcomes

  1. Physical exam, ECG, Vital signs and Laboratory tests, Drug interaction parameters

    Time frame: During study follow-up period

07

Study locations

1 site
  • Clinical Trial Center, Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
08

References and documents

Publications

  • Kim KP, Kim BH, Lim KS, Kim TE, Shin SG, Jang IJ, Yu KS. Potential interactions between cilostazol and probucol: a two-part, single-dose, open-label study in healthy Korean male volunteers. Clin Ther. 2009 Oct;31(10):2098-106. doi: 10.1016/j.clinthera.2009.10.005. PubMed 19922880 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of May 2008 and a completion of Aug 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 25, 2007
First posted
Oct 26, 2007
Start
Oct 2007
Primary completionActual
May 2008
CompletionActual
Aug 2008
Last update
Mar 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00549978
Responsible party
Sponsor
First posted
Oct 26, 2007
Start date
Oct 2007
Primary completion
May 2008
Completion
Aug 2008
Last update
Mar 4, 2022

Study contacts

In-Jin Jang, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cilostazol · Probucol

Start the discussion